← FDA DRUG APPROVALS

FDA ANDA · ANDA091048

CEFEPIME HYDROCHLORIDE

Sponsor: SAGENT PHARMS INC

APPLICATION
ANDA091048
TYPE
ANDA
ORIGINAL APPROVAL
2017-01-04
LATEST ACTION
2020-05-21
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

CEFEPIME HYDROCHLORIDEPrescription
CEFEPIME HYDROCHLORIDE EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
CEFEPIME HYDROCHLORIDEPrescription
CEFEPIME HYDROCHLORIDE EQ 1GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2020-05-21Labeling · Supplement 4 · standardAP
2017-08-15Labeling · Supplement 2 · standardAP
2017-01-04OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →